Abstract
Background: Cisplatin (CDDP)-induced acute kidney injury (AKI) involves pro-inflammatory responses, apoptosis of renal tubular epithelial cells and vascular damage. AKI increases the risk of chronic kidney disease. Relaxin (RLX) has anti-apoptotic and anti-fibrosis properties. The aim of this study was to investigate the effects of RLX on CDDP-induced nephrotoxicity. Methods: We investigated the mitigating effects of RLX based on the etiopathology of AKI induced by CDDP, and also the anti-fibrotic effect of RLX on renal fibrosis after AKI. In the short-term experiments, rats were divided into the control group, CDDP group, and CDDP+RLX group. In the latter group, RLX was infused for 5 or 14 days using an implanted osmotic minipump. CDDP was injected intraperitoneally (6 mg/kg) after RLX or saline infusion. At 5 and 14 days post-CDDP, the kidneys were removed for analysis. The effect of RLX on renal fibrosis after AKI was evaluated at 6 weeks post-CDDP. Results: In short-term experiments, CDDP transiently increased plasma creatinine and blood urea nitrogen with peaks at day 5, and RLX prevented such rises. Semiquantitative analysis of the histological lesions indicated marked structural damage and apoptotic cells in the CDDP group, with the lesions being reduced by RLX treatment. Overexpression of Bax, interleukin-6 and tumor necrosis factor-α observed in the kidneys of the CDDP group was reduced in the CDDP+RLX group. In the long-term experiments, RLX significantly reduced renal fibrosis compared with the CDDP group. Conclusions: The results suggested that RLX provided protection against CDDP-induced AKI and subsequent fibrosis by reducing apoptosis and inflammation.
Journal Section:
Original Paper
References
1.
Madias NE, Harrington JT: Platinum nephrotoxicity. Am J Med 1978;65:307-314.
[PubMed]
2.
Caglar K, Kinalp C, Arpaci F, Turan M, Saglam K, Ozturk B, Komurcu S, Yavuz I, Yenicesu M, Ozet A, Vural A: Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation. Nephrol Dial Transplant 2002;17:1931-1935.
[PubMed]
3.
Sato K, Kusaka Y, Zhang Q, Zhu X, Okada K: Effect of platinum coordination complex (PtCx) on citrate uptake by rat renal brush border membrane vesicles (BBMV): direct effect of cisplatin. Ind Health 2000;38:327-329.
[PubMed]
4.
Jiang M, Dong Z: Regulation and pathological role of p53 in cisplatin nephrotoxicity. J Pharmacol Exp Ther 2008;327:300-307.
[PubMed]
5.
Guinee DG Jr, van Zee B, Houghton DC: Clinically silent progressive renal tubulointerstitial disease during cisplatin chemotherapy. Cancer 1993;71:4050-4054.
[PubMed]
6.
Samuel CS, Cendrawan S, Gao XM, Ming Z, Zhao C, Kiriazis H, Xu Q, Tregear GW, Bathgate RA, Du XJ: Relaxin remodels fibrotic healing following myocardial infarction. Lab Invest 2011;91:675-690.
[PubMed]
7.
Unemori EN, Pickford LB, Salles AL, Piercy CE, Grove BH, Erikson ME, Amento EP: Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 1996;98:2739-2745.
[PubMed]
8.
Yoshida T, Kumagai H, Suzuki A, Kobayashi N, Ohkawa S, Odamaki M, Kohsaka T, Yamamoto T, Ikegaya N: Relaxin ameliorates salt-sensitive hypertension and renal fibrosis. Nephrol Dial Transplant 2012;27:2190-2197.
[PubMed]
9.
Cosen-Binker LI, Binker MG, Cosen R, Negri G, Tiscornia O: Relaxin prevents the development of severe acute pancreatitis. World J Gastroenterol 2006;12:1558-1568.
[PubMed]
10.
Pema AM, Masini E, Nistri S, Briganti V, Chiappini L, Stefano P, Bigazzi M, Pieroni C, Bani Sacchi T, Bani D: Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model. FASEB J 2005;11:1525-1527.
[PubMed]
11.
Yoshida T, Kumagai H, Kohsaka T, Ikegaya N: Relaxin protects against renal ischemia reperfusion injury. Am J Physiol Renal Physiol 2013;305:F1169-F1176.
[PubMed]
12.
Collino M1, Rogazzo M, Pini A, Benetti E, Rosa AC, Chiazza F, Fantozzi R, Bani D, Masini E: Acute treatment with relaxin protects the kidney against ischaemia/reperfusion injury. J Cell Mol Med 2013;17:1494-1505.
[PubMed]
13.
Danielson LA, Sherwood OD, Conrad KP: Relaxin is a potent renal vasodilator in conscious rats. J Clin Invest 1999;103:525-533.
[PubMed]
14.
Kato S, Siqin, Minagawa I, Aoshima T, Sagata D, Konishi H, Yogo K, Kawarasaki T, Sasada H, Tomogane H, Kohsaka T: Evidence for expression of relaxin hormone-receptor system in the boar testis. J Endocrinol 2010;207:135-149.
[PubMed]
15.
Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, Gordon KL, Mazzali M, Jefferson JA, Hughes J, Madsen KM, Schreiner GF, Johnson RJ: Impaired angiogenesis in the remnant kidney model. I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 2001;12:1434-1447.
[PubMed]
16.
Kumagai H, Katoh S, Hirosawa K, Kimura M, Hishida A, Ikegaya N: Renal tubulointerstitial injury in weanling rats with hyperhomocysteinemia. Kidney Int 2002;62:1219-1228.
[PubMed]
17.
Pabla N, Dong Z: Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008;73:994-1007.
[PubMed]
18.
Park JW, Cho JW, Joo SY, Kim CS, Choi JS, Bae EH, Ma SK, Kim SH, Lee J, Kim SW: Paricalcitol prevents cisplatin-induced renal injury by suppressing apoptosis and proliferation. Eur J Pharmacol 2012;683:301-309.
[PubMed]
19.
Dieckmann KP, Struss WJ, Budde U: Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour. Anticancer Res 2011;31:4501-4505.
[PubMed]
20.
Bonacchi M, Nistri S, Gelsomino S, Gelsomino S, Pini A, Cinci L, Maiani M, Zecchi-Orlandini S, Lorusso R, Fanti S, Silvertown J, Bani D: Functional and histopathological improvement of the post-infarcted rat heart upon myoblast cell grafting and relaxin therapy. J Cell Mol Med 2009;13:3437-3448.
[PubMed]
21.
Masini E, Cuzzocrea S, Mazzon E, Muià C, Vannacci A, Fabrizi F, Bani D: Protective effects of relaxin in ischemia-reperfusion-induced intestinal injury due to splanchnic artery occlusion. Br J Pharmacol 2006;148:1124-1132.
[PubMed]
22.
Moore XL, Tan SL, Lo CY, Fang L, Su YD, Gao XM, Woodcock EA, Summers RJ, Tregear GW, Bathgate RA, Du XJ: Relaxin antagonizes hypertrophy and apoptosis in neonatal rat cardiomyocytes. Endocrinology 2007;148:1582-1589.
[PubMed]
23.
Donnahoo KK, Meldrum DR, Shenkar R, Chung CS, Abraham E, Harken AH: Early renal ischemia, with or without reperfusion, activates NF-κB and increases TNF-α bioactivity in the kidney. J Urol 2000;163:1328-1332.
[PubMed]
24.
Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA, Edelstein CL: Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1β, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther 2007;322:8-15.
[PubMed]
25.
Ramesh G, Reeves WB: TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002;110:835-842.
[PubMed]
26.
Nath KA, Croatt AJ, Haggard JJ, Grande JP: Renal response to repetitive exposure to heme proteins: chronic injury induced by an acute insult. Kidney Int 2000;57:2423-2433.
[PubMed]
27.
Kawai Y, Satoh T, Hibi D, Ohno Y, Kohda Y, Miura K, Gemba M: The effect of antioxidant on development of fibrosis by cisplatin in rats. J Pharmacol Sci 2009;111:433-439.
[PubMed]
28.
Nangaku M: Mechanisms of tubulointerstitial injury in the kidney final common pathways to end-stage renal failure. Intern Med 2004;43:9-17.
[PubMed]
© 2014 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.
